Homology Medicines Inc
NASDAQ:FIXX
Homology Medicines Inc
EPS (Diluted)
Homology Medicines Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Homology Medicines Inc
NASDAQ:FIXX
|
EPS (Diluted)
-$1
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$3
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$33
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Homology Medicines Inc's EPS (Diluted)?
EPS (Diluted)
-2
USD
Based on the financial report for Dec 31, 2023, Homology Medicines Inc's EPS (Diluted) amounts to -2 USD.
What is Homology Medicines Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
0%
Over the last year, the EPS (Diluted) growth was -2 067%. The average annual EPS (Diluted) growth rates for Homology Medicines Inc have been 11% over the past three years .